Abstract
One of the main pathological characteristics of Alzheimers disease is the presence in the brain of the patients of an aberrant structure, the paired helical filaments, composed of hyperphosphorylated tau. The level of tau phosphorylation has been correlated with the capacity for tau aggregation. Thus, the mechanism for tau phosphorylation could be important to clarify those pathological features in Alzheimers disease. Tau protein could be modified by different kinases, being GSK3 the one that could modify more sites of that protein. GSK3 activity could be modulate by the presence of metals like magnesium that can be required for the proper function of the kinase, whereas, metals like manganesum or lithium inhibit the activity of the kinase. Many works have been done to study the inhibition of GSK3 by lithium, a specific inhibitor of that kinase. More recently, it has been indicated that sodium tungstate could also inhibit GSK3 through a different mechanism. In this review, we discuss the effect of these two metals, lithium and tungstate, on GSK3 (or tau I kinase) activity.
Keywords: tau kinase, GSK3 inhibition, insulin degrading enzyme (IDE), glycogen synthase (GS), Alzheimer, ’, s disease
Current Alzheimer Research
Title: Inhibition of GSK3 Dependent Tau Phosphorylation by Metals
Volume: 3 Issue: 2
Author(s): Alberto Gomez-Ramos, Jorge Dominguez, Delia Zafra, Helena Corominola, Ramon Gomis, Joan J. Guinovart and Jesus Avila
Affiliation:
Keywords: tau kinase, GSK3 inhibition, insulin degrading enzyme (IDE), glycogen synthase (GS), Alzheimer, ’, s disease
Abstract: One of the main pathological characteristics of Alzheimers disease is the presence in the brain of the patients of an aberrant structure, the paired helical filaments, composed of hyperphosphorylated tau. The level of tau phosphorylation has been correlated with the capacity for tau aggregation. Thus, the mechanism for tau phosphorylation could be important to clarify those pathological features in Alzheimers disease. Tau protein could be modified by different kinases, being GSK3 the one that could modify more sites of that protein. GSK3 activity could be modulate by the presence of metals like magnesium that can be required for the proper function of the kinase, whereas, metals like manganesum or lithium inhibit the activity of the kinase. Many works have been done to study the inhibition of GSK3 by lithium, a specific inhibitor of that kinase. More recently, it has been indicated that sodium tungstate could also inhibit GSK3 through a different mechanism. In this review, we discuss the effect of these two metals, lithium and tungstate, on GSK3 (or tau I kinase) activity.
Export Options
About this article
Cite this article as:
Gomez-Ramos Alberto, Dominguez Jorge, Zafra Delia, Corominola Helena, Gomis Ramon, Guinovart J. Joan and Avila Jesus, Inhibition of GSK3 Dependent Tau Phosphorylation by Metals, Current Alzheimer Research 2006; 3 (2) . https://dx.doi.org/10.2174/156720506776383059
DOI https://dx.doi.org/10.2174/156720506776383059 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ligand and Structure-Based Drug Design as Strategies for the Screening of New BACE1 Inhibitor Candidates
Current Physical Chemistry Metabolic Dysfunction in Alzheimers Disease and Related Neurodegenerative Disorders
Current Alzheimer Research Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential
Current Aging Science High Serum Alkaline Phosphatase Levels in Relation to Multi-Cerebral Microbleeds in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Advanced Glycation End Products, Oxidative Stress and Metalloproteinases are altered in the Cerebral Microvasculature during Aging
Current Neurovascular Research Novel Biosynthesis, Metabolism and Physiological Functions of L-Homoarginine
Current Protein & Peptide Science Update of QSAR & Docking Studies of the GSK-3 Inhibitors
Current Bioinformatics Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology Triheptanoin Supplementation to Ketogenic Diet Curbs Cognitive Impairment in APP/PS1 Mice Used as a Model of Familial Alzheimer’s Disease
Current Alzheimer Research Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Advances in Neuroimaging for HIV-1 Associated Neurological Dysfunction: Clues to the Diagnosis, Pathogenesis and Therapeutic Monitoring
Current HIV Research Conference Report: The Myriad Pathways of Neurodegeneration Discussed at NEUROCON 2015
Current Aging Science Importance of P-gp PET Imaging in Pharmacology
Current Pharmaceutical Design Therapeutic Potential of Cannabinoids in Schizophrenia
Recent Patents on CNS Drug Discovery (Discontinued) Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches
Current Drug Targets Functional Magnetic Resonance Imaging in Abstinent MDMA Users: A Review
Current Drug Abuse Reviews Elicitation of Immune Responsiveness Against Antigenic Challenge in Age- Related Diseases: Effects of Red Wine Polyphenols
Current Pharmaceutical Design GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia
Current Neuropharmacology Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer’s Disease
Current Medicinal Chemistry